Prolacting's role in the pathogenesis of the antiphospholipid syndrome

Lupus

Volumn 19, Issue 13, 2010, Pages 1515-1519

  Praprotnik, S ^a   Agmon Levin, N ^b   Porat Katz, B S ^c   Blank, M ^b   Meroni, P L ^d   Cervera, R ^e   Miesbach, W ^f   Stojanovich, L ^g   Szyper Kravitz, M ^b   Rozman, B ^a   Tomsic, M ^a   Shoenfeld, Y ^b,h  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b SHEBA MEDICAL CENTER   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d UNIVERSITY OF MILAN   (Italy)

^e HOSPITAL CLÍNIC   (Spain)

^f GOETHE UNIVERSITY   (Germany)

^g Bezhanijska Kosa University Medical Center   (Serbia)

^h TEL AVIV UNIVERSITY   (Israel)

Author keywords

antiphospholipid antibodies; antiphospholipid syndrome; hyperprolactinaemia; prolactin; reproductive failure

Indexed keywords

PHOSPHOLIPID ANTIBODY; PROLACTIN;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; HYPERPROLACTINEMIA; INTRAUTERINE GROWTH RETARDATION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; BLOOD; CASE CONTROL STUDY; EUROPE; MIDDLE AGED; PATHOPHYSIOLOGY; PREGNANCY; SPONTANEOUS ABORTION;

ABORTION, SPONTANEOUS; ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; CASE-CONTROL STUDIES; EUROPE; FEMALE; FETAL GROWTH RETARDATION; HUMANS; HYPERPROLACTINEMIA; MALE; MIDDLE AGED; PREGNANCY; PROLACTIN;

EID: 78649289804     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203310373781     Document Type: Article

References (24)

1. Orbach H., Shoenfeld Y. Hyperprolactinemia and autoimmune diseases. Autoimmun Rev 2007 ; 6: 537-542.
2. Peeva E., Venkatesh J., Michael D., Diamond B. Prolactin as a modulator of B cell function; implications for SLE. Biomed Pharmacother 2004 ; 58: 310-319.
3. Saha S., Gonzalez J., Rosenfeld G., Keiser H., Peeva E. Prolactin alters the mechanisms of B cell tolerance induction. Arthritis Rheum 2009 ; 60: 1743-1752.
4. Krause I., Blumenfeld Z., Malchinsky M., et al. Anti-endothelial cell antibodies in the sera of hyperprolactinemic women. Lupus 1998 ; 7: 377-382.
5. Chikanza IC Prolactin and neuroimmunomodulation: in vitro and in vivo observations. Ann N Y Acad Sci 1999 ; 876: 119-130.
6. De Bellis A., Bizzarro A., Pivonello R., Lombardi G., Bellastella A. Prolactin and autoimmunit. Pituitary 2005 ; 8: 25-30.
7. Leanos-Miranda A., Cardenas-Mondragon G. Serum free prolactin concentrations in patients with systemic lupus erythematosus are associated with lupus activity. Rheumatology 2006 ; 45: 97-101.
8. Peeva E., Grimaldi C., Spatz L., Diamond B. Bromocriptine restores tolerance in estrogen-treated mice. J Clin Invest 2000 ; 106: 1373-1379.
9. Buskila D., Lorber M., Neumann L., Flusser D., Shoenfeld Y. No correlation between prolactin levels and clinical activity in patients with systemic lupus erythematosus. J Rheumatol 1996 ; 23: 629-632. (Pubitemid 26139634)
10. Peeva E., Zouali M. Spotlight on the role of hormonal factors in the emergence of autoreactive B-lymphocytes. Immunol Lett 2005 ; 101: 123-143.
11. Blank M., Krause I., Buskila D., et al. Bromocriptine immunomodulation of experimental SLE and primary antiphospholipid syndrome via induction of nonspecific T suppressor cells. Cell Immunol 1995 ; 162: 114-122.
12. McMurray RW, Weidensaul D., Allen SH, Walker SE Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus. J Rheumatol 1995 ; 22: 2084-2091.
13. Alvarez-Nemegyei J., Cobarrubias-Cobos A., Escalante-Triay F., Sosa-Munoz J., Miranda JM, Jara LJ Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study. Lupus 1998 ; 7: 414-419.
14. Pierangeli SS, Chen PP, Rashi E., et al. Atiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost 2008 ; 34: 236-250.
15. Ronis T., Duffy CM, Wataname Duffy KN Galactorrhea associated with juvenile systemic lupus erythematosus: a review of the role of prolactin. Pediatr Rheumatol Online J 2009 ; 7: 17.
16. Wallaschofski H., Kobsar A., Sokolova O., et al. Co-activation of platelets by prolactin or leptin - pathophysiological findings and clinical implications. Horm Metab Res 2004 ; 36: 1-6.
17. Wallaschofski H., Kobsar A., Koksch M., et al. Prolactin receptor signalling during platelet activation. Horm Metab Res 2003 ; 35: 228-235.
18. Reuwer AQ, Nieuwland R., Fernandes I., et al. Prolactin does not affect human platelet aggregation or secretion. Thromb Haemost 2009 ; 101: 1119-1127.
19. Danovski A., deAzevedo MN, de Souza Papi JA, Petri M. Determinants of risk factors for venous or arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol 2009 ; 36: 1195-1199.
20. Jara LJ, Pacheco Reyes H., Medina G., et al. Prolactin levels are associated with lupus activity, lupus anticoagulant, and poor outcome in pregnancy. Ann N Y Acad Sci 2007 ; 1108: 218-226.
21. Blank M., Shoenfeld Y. Antiphospholipid antibody-mediated reproductive failure in antiphospholipid syndrome. Clinic Rev Allerg Immunol 2010 ; 38: 141-147.
22. Di Simone N., Raschi E., Testoni C., et al. Pathogenic role of anti-beta 2-glycoprotein I antibodies in antiphospholipid associated fetal loss: characterisation of beta 2-glycoprotein I binding to trophoblast cells and functional effects of anti-beta 2-glycoprotein I antibodies in vitro. Ann Rheum Dis 2005 ; 64: 462-467.
23. Mak IY, Brosens JJ, Christian M., et al. Regulated expression of signal transducer and activator of transcription, Stat5, and its enhancement of PRL expression in human endometrial stromal cells in vitro. J Clin Endocrinol Metab 2002 ; 87: 2581-2588.
24. Hu D., Cross JC Development and function of trophoblast giant cell in the rodent placenta. Int J Dev Biol 2010 ; 54: 341-354.